{"id":341401,"date":"2026-11-06T10:38:48","date_gmt":"2026-11-06T05:08:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=341401"},"modified":"2026-11-06T10:38:48","modified_gmt":"2026-11-06T05:08:48","slug":"research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/","title":{"rendered":"3 Research Driven Pharma Company, Instrument Clusters Maker and Multi Speciality Hospital Network Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Pricol and Fortis Healthcare"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Glenmark Pharmaceuticals, Pricol and Fortis Healthcare: ROE of 10.5% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 27.1%. Prices as of 5 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three research drug, dashboard part, hospital stocks to watch are Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Their return on equity ranges from 10.5% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.1%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Pricol has the fastest revenue growth at 27.1% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Research drug, dashboard part, hospital stocks bring together companies with a visible plan for the years ahead. Glenmark Pharmaceuticals, Pricol and Fortis Healthcare cover a research driven pharma company, an instrument clusters maker and a multi speciality hospital network.<\/p>\n<p>This list covers three research drug, dashboard part, hospital stocks with complete current figures: Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#What_Are_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"What Are Research Drug, Dashboard Part, Hospital Stocks?\">What Are Research Drug, Dashboard Part, Hospital Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Research_Drug_Dashboard_Part_Hospital_Stocks_at_a_Glance\" title=\"Research Drug, Dashboard Part, Hospital Stocks at a Glance\">Research Drug, Dashboard Part, Hospital Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Why_Do_Research_Drug_Dashboard_Part_Hospital_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Research Drug, Dashboard Part, Hospital Stocks Have a Strong Roadmap in India?\">Why Do Research Drug, Dashboard Part, Hospital Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Why_Glenmark_Pharmaceuticals_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"Why Glenmark Pharmaceuticals Features Among These Research Drug, Dashboard Part, Hospital Stocks\">Why Glenmark Pharmaceuticals Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Why_Pricol_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"Why Pricol Features Among These Research Drug, Dashboard Part, Hospital Stocks\">Why Pricol Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Why_Fortis_Healthcare_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"Why Fortis Healthcare Features Among These Research Drug, Dashboard Part, Hospital Stocks\">Why Fortis Healthcare Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Glenmark_Pharmaceuticals_vs_Pricol_vs_Fortis_Healthcare_on_Key_Financials\" title=\"Glenmark Pharmaceuticals vs Pricol vs Fortis Healthcare on Key Financials\">Glenmark Pharmaceuticals vs Pricol vs Fortis Healthcare on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Key_Risks_to_Check_Before_Investing_in_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"Key Risks to Check Before Investing in Research Drug, Dashboard Part, Hospital Stocks\">Key Risks to Check Before Investing in Research Drug, Dashboard Part, Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Final_Thoughts_on_Research_Drug_Dashboard_Part_Hospital_Stocks\" title=\"Final Thoughts on Research Drug, Dashboard Part, Hospital Stocks\">Final Thoughts on Research Drug, Dashboard Part, Hospital Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#What_are_research_drug_dashboard_part_hospital_stocks\" title=\"What are research drug, dashboard part, hospital stocks?\">What are research drug, dashboard part, hospital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Which_research_drug_dashboard_part_hospital_stocks_are_covered_in_this_list\" title=\"Which research drug, dashboard part, hospital stocks are covered in this list?\">Which research drug, dashboard part, hospital stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Why_do_research_drug_dashboard_part_hospital_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do research drug, dashboard part, hospital stocks have a strong future roadmap in India?\">Why do research drug, dashboard part, hospital stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#How_has_Glenmark_Pharmaceuticals_performed_financially\" title=\"How has Glenmark Pharmaceuticals performed financially?\">How has Glenmark Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#How_has_Pricol_performed_financially\" title=\"How has Pricol performed financially?\">How has Pricol performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#How_has_Fortis_Healthcare_performed_financially\" title=\"How has Fortis Healthcare performed financially?\">How has Fortis Healthcare performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#What_risks_should_investors_check_before_buying_research_drug_dashboard_part_hospital_stocks\" title=\"What risks should investors check before buying research drug, dashboard part, hospital stocks?\">What risks should investors check before buying research drug, dashboard part, hospital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality-hospital-network-stocks-roadmap-treeline-list\/#Is_this_list_of_research_drug_dashboard_part_hospital_stocks_investment_advice\" title=\"Is this list of research drug, dashboard part, hospital stocks investment advice?\">Is this list of research drug, dashboard part, hospital stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>What Are Research Drug, Dashboard Part, Hospital Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Research drug, dashboard part, hospital stocks are listed companies that develop and sell branded generics and specialty medicines, make instrument clusters and driver information systems for vehicles, and run multi-speciality hospitals across India. Their earnings depend on drug approvals, vehicle output and patient volumes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Research_Drug_Dashboard_Part_Hospital_Stocks_at_a_Glance\"><\/span><strong>Research Drug, Dashboard Part, Hospital Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,481.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">60,103<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/pricolltd\/pricol-ltd-share-price-today\">Pricol<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">727.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,072<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.30<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/fortis\/fortis-healthcare-ltd-share-price-today\">Fortis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">819.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">55,554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">51.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.35<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing research drug, dashboard part, hospital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in research drug, dashboard part, hospital stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Research_Drug_Dashboard_Part_Hospital_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Research Drug, Dashboard Part, Hospital Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Research drug, dashboard part, hospital stocks have a strong roadmap in India because wider demand for specialty medicines, rising vehicle electronics content and growing demand for advanced care keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pharma.<\/strong> Specialty medicines reach more markets.<\/li>\n<li><strong>Instrument clusters.<\/strong> Modern vehicles carry digital displays.<\/li>\n<li><strong>Hospitals.<\/strong> Patients seek advanced care.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Glenmark_Pharmaceuticals_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>Why Glenmark Pharmaceuticals Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the research drug, dashboard part, hospital stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.<\/p>\n<p>Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.<\/p>\n<p>In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.<\/p>\n<p><strong>What to watch:<\/strong> Track new product launches, progress in the innovation pipeline and balance sheet strength.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Pricol_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>Why Pricol Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma, auto part and health shares on this list, Pricol, based in Coimbatore, makes instrument clusters, driver information systems, sensors and pumps for two-wheelers, commercial vehicles and off-highway vehicles.<\/p>\n<p>In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%.<\/p>\n<p>Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P\/E of 30.1, below the industry P\/E of 36.9.<\/p>\n<p><strong>Roadmap:<\/strong> Digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.<\/p>\n<p><strong>What to watch:<\/strong> Track the shift to digital clusters and the progress of new product ramp-ups.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Fortis_Healthcare_Features_Among_These_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>Why Fortis Healthcare Features Among These Research Drug, Dashboard Part, Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.<\/p>\n<p>The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.<\/p>\n<p><strong>What to watch:<\/strong> Track bed additions, occupancy and revenue per occupied bed.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Glenmark_Pharmaceuticals_vs_Pricol_vs_Fortis_Healthcare_on_Key_Financials\"><\/span><strong>Glenmark Pharmaceuticals vs Pricol vs Fortis Healthcare on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three research drug, dashboard part, hospital stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Glenmark Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,472<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,443<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,362<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Pricol<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,052<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">251<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,745<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,178<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,064<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Pricol shows the fastest revenue growth with a 27.1% compound annual rate. A useful habit with research drug, dashboard part, hospital stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Glenmark Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,291<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,084<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Pricol<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">898<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,108<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,182<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,560<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Research Drug, Dashboard Part, Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these research drug, dashboard part, hospital stocks, the main points are: Long-term pharma, auto part and health shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter research drug, dashboard part, hospital stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Research_Drug_Dashboard_Part_Hospital_Stocks\"><\/span><strong>Final Thoughts on Research Drug, Dashboard Part, Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Research drug, dashboard part, hospital stocks suit investors who prefer to study business strength before price moves. Glenmark Pharmaceuticals, Pricol and Fortis Healthcare each have a clear plan to grow. Based on the 5 November 2026 close, Glenmark Pharmaceuticals trades at Rs 2,481.8, Pricol at Rs 727.9 and Fortis Healthcare at Rs 819.8. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these research drug, dashboard part, hospital stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track research drug, dashboard part, hospital stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_research_drug_dashboard_part_hospital_stocks\"><\/span><strong>What are research drug, dashboard part, hospital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Research drug, dashboard part, hospital stocks are listed companies that develop and sell branded generics and specialty medicines, make instrument clusters and driver information systems for vehicles, and run multi-speciality hospitals across India. Their earnings depend on drug approvals, vehicle output and patient volumes. This list looks at three of them, Glenmark Pharmaceuticals, Pricol and Fortis Healthcare, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_research_drug_dashboard_part_hospital_stocks_are_covered_in_this_list\"><\/span><strong>Which research drug, dashboard part, hospital stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Based on the 5 November 2026 close, Glenmark Pharmaceuticals traded at Rs 2,481.8, Pricol at Rs 727.9 and Fortis Healthcare at Rs 819.8. Their return on equity ranges from 10.5% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_research_drug_dashboard_part_hospital_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do research drug, dashboard part, hospital stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Research drug, dashboard part, hospital stocks have a strong roadmap in India because wider demand for specialty medicines, rising vehicle electronics content and growing demand for advanced care keep widening the market for these companies. The main drivers are as follows. Pharma. Specialty medicines reach more markets. Instrument clusters. Modern vehicles carry digital displays. Hospitals. Patients seek advanced care. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Glenmark_Pharmaceuticals_performed_financially\"><\/span><strong>How has Glenmark Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Pricol_performed_financially\"><\/span><strong>How has Pricol performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P\/E of 30.1, below the industry P\/E of 36.9. Looking ahead, digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Fortis_Healthcare_performed_financially\"><\/span><strong>How has Fortis Healthcare performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_research_drug_dashboard_part_hospital_stocks\"><\/span><strong>What risks should investors check before buying research drug, dashboard part, hospital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying research drug, dashboard part, hospital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_research_drug_dashboard_part_hospital_stocks_investment_advice\"><\/span><strong>Is this list of research drug, dashboard part, hospital stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are research drug, dashboard part, hospital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Research drug, dashboard part, hospital stocks are listed companies that develop and sell branded generics and specialty medicines, make instrument clusters and driver information systems for vehicles, and run multi-speciality hospitals across India. Their earnings depend on drug approvals, vehicle output and patient volumes. This list looks at three of them, Glenmark Pharmaceuticals, Pricol and Fortis Healthcare, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which research drug, dashboard part, hospital stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Based on the 5 November 2026 close, Glenmark Pharmaceuticals traded at Rs 2,481.8, Pricol at Rs 727.9 and Fortis Healthcare at Rs 819.8. Their return on equity ranges from 10.5% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do research drug, dashboard part, hospital stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Research drug, dashboard part, hospital stocks have a strong roadmap in India because wider demand for specialty medicines, rising vehicle electronics content and growing demand for advanced care keep widening the market for these companies. The main drivers are as follows. Pharma. Specialty medicines reach more markets. Instrument clusters. Modern vehicles carry digital displays. Hospitals. Patients seek advanced care. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Glenmark Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.\"}},{\"@type\":\"Question\",\"name\":\"How has Pricol performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P\/E of 30.1, below the industry P\/E of 36.9. Looking ahead, digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.\"}},{\"@type\":\"Question\",\"name\":\"How has Fortis Healthcare performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying research drug, dashboard part, hospital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying research drug, dashboard part, hospital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of research drug, dashboard part, hospital stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Research Drug, Dashboard Part, Hospital Stocks with a strong future roadmap: Glenmark Pharmaceuticals, Pricol and Fortis Healthcare. Compare price, valuation, return on equity and revenue growth as of 5 November 2026.<\/p>\n","protected":false},"author":29,"featured_media":341400,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[20598,3803,20927,20925,7543,15753,5141,20926,5930,20924],"class_list":["post-341401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-auto-part-and-health-shares","tag-best-stocks","tag-dashboard-and-tertiary-care-stocks","tag-dashboard-part","tag-fortis-healthcare","tag-glenmark-pharmaceuticals","tag-hospital-stocks","tag-innovative-pharma","tag-pricol","tag-research-drug"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["341400"],"rank_math_title":["Research Drug, Instrument Cluster and Hospital Stocks"],"rank_math_description":["Compare 3 research drug, dashboard part, hospital stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 5 Nov 2026."],"rank_math_focus_keyword":["research drug, dashboard part, hospital stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-research-driven-pharma-company-instrument-clusters-maker-and-multi-speciality.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=341401"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341401\/revisions"}],"predecessor-version":[{"id":341402,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341401\/revisions\/341402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/341400"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=341401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=341401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=341401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}